{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:04:07Z","timestamp":1782954247861,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,7]]},"DOI":"10.7759\/cureus.26642","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T19:02:38Z","timestamp":1657220558000},"source":"Crossref","is-referenced-by-count":10,"title":["Effects of Renin-Angiotensin-Aldosterone System Inhibition on Left Ventricular Hypertrophy, Diastolic Function, and Functional Status in Patients With Hypertrophic Cardiomyopathy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Hamza","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al Sudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehr un Nisa","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c130040","article-title":"Classical renin-angiotensin system in kidney physiology","volume":"4","author":"Sparks MA","year":"2014","unstructured":"Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014, 4:1201-28. 10.1002\/cphy.c130040","journal-title":"Compr Physiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0840001","article-title":"Cellular and intrarenal control of renin secretion","volume":"84","author":"Sk\u00f8tt O","year":"1993","unstructured":"Sk\u00f8tt O, Jensen BL. Cellular and intrarenal control of renin secretion. Clin Sci (Lond). 1993, 84:1-10. 10.1042\/cs0840001","journal-title":"Clin Sci (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1565055","article-title":"Aldosterone and left ventricular remodeling","volume":"47","author":"Catena C","year":"2015","unstructured":"Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and left ventricular remodeling. Horm Metab Res. 2015, 47:981-6. 10.1055\/s-0035-1565055","journal-title":"Horm Metab Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.73.3.413","article-title":"Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype","volume":"73","author":"Sadoshima J","year":"1993","unstructured":"Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993, 73:413-23. 10.1161\/01.res.73.3.413","journal-title":"Circ Res"},{"key":"ref5","article-title":"Inhibition of the renin angiotensin aldosterone system: focus on aliskiren","volume":"58","author":"Rao MS","year":"2010","unstructured":"Rao MS. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren. J Assoc Physicians India. 2010, 58:102-8.","journal-title":"J Assoc Physicians India"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.12.010","article-title":"Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: network meta-analysis","volume":"205","author":"Xie W","year":"2016","unstructured":"Xie W, Zheng F, Song X, Zhong B, Yan L. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: network meta-analysis. Int J Cardiol. 2016, 205:65-71. 10.1016\/j.ijcard.2015.12.010","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah MH","year":"2006","unstructured":"Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2006, 47:1576-83. 10.1016\/j.jacc.2005.11.073","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.01.009","article-title":"Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction","volume":"125","author":"Kuno T","year":"2020","unstructured":"Kuno T, Ueyama H, Fujisaki T, Briasouli A, Takagi H, Briasoulis A. Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction. Am J Cardiol. 2020, 125:1187-93. 10.1016\/j.amjcard.2020.01.009","journal-title":"Am J Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy","volume":"103","author":"Lim DS","year":"2001","unstructured":"Lim DS, Lutucuta S, Bachireddy P, et al.. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001, 103:789-91. 10.1161\/01.cir.103.6.789","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson A","year":"2015","unstructured":"Axelsson A, Iversen K, Vejlstrup N, et al.. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015, 3:123-31. 10.1016\/S2213-8587(14)70241-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy","volume":"1","author":"Shimada YJ","year":"2013","unstructured":"Shimada YJ, Passeri JJ, Baggish AL, et al.. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013, 1:480-7. 10.1016\/j.jchf.2013.09.001","journal-title":"JACC Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.48.715","article-title":"A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker","volume":"48","author":"Yamazaki T","year":"2007","unstructured":"Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K, Nagai R. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J. 2007, 48:715-24. 10.1536\/ihj.48.715","journal-title":"Int Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study","volume":"11","author":"Penicka M","year":"2009","unstructured":"Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009, 11:35-41. 10.2353\/jmoldx.2009.080082","journal-title":"J Mol Diagn"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron MS","year":"2018","unstructured":"Maron MS, Chan RH, Kapur NK, et al.. Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy. Am J Med. 2018, 131:837-41. 10.1016\/j.amjmed.2018.02.025","journal-title":"Am J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1253\/circj.69.1244","article-title":"Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy","volume":"69","author":"Kawano H","year":"2005","unstructured":"Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J. 2005, 69:1244-8. 10.1253\/circj.69.1244","journal-title":"Circ J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy","volume":"96","author":"Araujo AQ","year":"2005","unstructured":"Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005, 96:1563-7. 10.1016\/j.amjcard.2005.07.065","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011942824139","article-title":"Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters","volume":"224","author":"Masutomo K","year":"2001","unstructured":"Masutomo K, Makino N, Fushiki MS. Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. Mol Cell Biochem. 2001, 224:19-27. 10.1023\/a:1011942824139","journal-title":"Mol Cell Biochem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103064-effects-of-renin-angiotensin-aldosterone-system-inhibition-on-left-ventricular-hypertrophy-diastolic-function-and-functional-status-in-patients-with-hypertrophic-cardiomyopathy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:31Z","timestamp":1707507571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103064-effects-of-renin-angiotensin-aldosterone-system-inhibition-on-left-ventricular-hypertrophy-diastolic-function-and-functional-status-in-patients-with-hypertrophic-cardiomyopathy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.26642","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}